Bonus BioGroup : Company Presentation

Innovative Tissue Regeneration Technologies

All information herein is the proprietary of Bonus BioGroup Ltd.

Disclaimer and Forward-Looking Statement

This presentation, both written and oral, includes statements that are, or may be deemed, ''forward-looking statements'' within the meaning of applicable securities laws. In some cases, these forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should," "approximately," "potential" or, in each case, their negative or other variations thereon or comparable terminology, although not all forward-looking statements contain these terms.

For example, when we discuss the addressable market sizes and growth potential of BonoFill and MesenCure, we are using forward-looking statements. Because such statements deal with future events, they are subject to various risks and uncertainties, and actual results, expressed or implied by such forward-looking statements, could differ materially from Bonus BioGroup's current beliefs, forecasts, and estimates. Factors that could cause or contribute to such differences include, but are not limited to risks and uncertainties associated with natural disasters and public health crises, such as the coronavirus disease (COVID) pandemic; the impact of global economic conditions; regulatory developments; our financing needs; research and development challenges; the demand and acceptance of our products and the other risk factors set forth in Bonus BioGroup's latest annual report and other filings with the Israeli Securities Authority ("ISA"). Any forward-looking statements that we make in this presentation, both written and oral, speaks only as of the date of such statement, and, except as required by applicable law, we undertake no obligation to update such statements to reflect events or circumstances after the date of this presentation.

This presentation, both written and oral, is not intended to provide you with a complete summary of Bonus BioGroup's business or financial results. For further information about us, you should read our reports and filings with the ISA. Our ISA filings are available athttp://www.magna.isa.gov.il andhttp://maya.tase.co.il.

This presentation, both written and oral, shall not constitute an offer to sell or the solicitation of an offer to buy any securities nor shall there be any sale by Bonus BioGroup of any securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

2

Who We Are

Bonus BioGroup is a clinical-stage biotechnology company focused on developing next-generation therapeutics in the fields of tissue regeneration and biotechnological products based on tissue engineering and cell therapy.

BonoFill™, our injectable human live bone graft, grown outside the patient body, based on their own cells, is undergoing a multi-center Phase II clinical trial in patients suffering from critical-sized defects in long bones, in five medical centers across Israel, and Phase II study in patients with critical-sized defects in craniomaxillofacial bones.

MesenCure™ is our cell therapy product, based on banked and professionalized cells derived from healthy donors. We have recently concluded a multi-center Phase II clinical trial in hospitalized, severe COVID patients suffering from pneumonia and life-threatening respiratory distress, demonstrating the efficacy and safety of MesenCure™ compared to the standard of care.

Our Vision:

Bonus BioGroup strives to become a global leader in Next-Generation Therapies in the fields of cell therapy and tissue engineering to improve human health.

Our mission is to help millions of people to live a better and longer life by merging innovative biological sciences and biomedical and biotechnology engineering.

Company Overview

* Bonus Therapeutics Ltd., a wholly owned subsidiary of Bonus BioGroup Ltd.

2008

Bonus* was founded by experts in tissue engineering and cell therapy led by Dr. Shai Meretzki, who pioneered the industrial development of mesenchymal cell therapies

2013

2014

Establishment of the world's first live human bone graft manufacturing facility, in Haifa, Israel. The facility is Good Manufacturing Practices (GMP) and ISO-9001 compliant

Launch of the first-in-human clinical trial with 1st generation BonoFillTM , an injectable bone graft for maxillofacial bone regeneration

2016

2017

Successful first-in-human demonstration of the safety and efficacy of 1st generation BonoFill™ and launch of the phase I/II clinical trial evaluating the safety and efficacy of 2nd generation BonoFillTM injectable bone graft for maxillofacial bone regeneration

Launch of the phase I/II clinical trial evaluating the safety and efficacy of BonoFillTM (2nd generation) injectable bone graft for bone regeneration in orthopedic indications

2019

Approval of Bonus BioGroup's primary patent for the generation and usage of 3D cell based bone implants in the US, followed by EU and AU

2020

Development of MesenCure, an innovative, cell-based therapy for the treatment of COVID associated pneumonia and inflammatory respiratory diseases and lunch of clinical trial

2021

Completed multi-center phase II clinical trial for treating severe COVID patients with MesenCure

2022/3

Planned launch of MesenCure multinational phase III clinical trial; and phase II/III clinical trial in the US evaluating the safety and efficacy of BonoFillTM injectable live bone graft for bone regeneration

4

Bonus' two cellular products set to transform their therapeutic areas

Designed for bone reconstruction as a result of various bone diseases, applicable in variable sizes of damages

Successfully demonstrated safety and efficacy in Phase 2 clinical trials for treating orthopedic and maxillofacial indications

Broad, early inhibition of the inflammatory cascade that result in treatment or prevention of ARDS in severe/critical COVID

Short IV administered course with immuno-evasive properties

No marketed MSC products for COVID or bone repair yet, despite the success of MSCs in other therapeutic areas

5